---

Cotec Healthcare Limited important data points

---

---

---

---

Cotec Healthcare Limited IPO Pros & Cons

Strengths:

• Strong positioning as a diversified pharmaceutical CDMO with multiple dosage-form capabilities.
• Wide customer base with pan-India presence and exports to multiple international markets.
• Established operating track record of over two decades in healthcare manufacturing.
• Increasing outsourcing trend in pharma manufacturing supports long-term growth.
• IPO proceeds aimed at capacity expansion and balance-sheet strengthening.

Risks:

• High dependence on a limited number of large customers could impact revenues.
• Pharma CDMO business faces strict regulatory and compliance risks.
• Intense competition from both domestic and global CDMO players.
• Margin pressure due to rising input and compliance costs.
• Valuation concerns may arise depending on final IPO price band.

Cotec Healthcare Limited Promoters – Pre offer equity (Approx)

Harsh Tiwari	~73.72%
Vandana Tiwari	~24.37%

Cotec Healthcare Limited Lot Size details

Application Type	Lot Size	No. of Lots	No. of Shares	Investment Amount
Retail(Min)	–	1	–	₹ –
Retail (Max)	–	13	–	₹ –
Small HNI (Min)	–	14	–	₹ –
Small HNI (Max)	–	66	–	₹ –
Big HNI (Min)	–	67	–	₹ –

Lead Managers / Registrars of Cotec Healthcare Limited 

Lead / Book Running Lead Managers	Pantomath Capital Advisors Private Limited
Registrar (RTA)	KFin Technologies Limited

Founding Year of Cotec Healthcare Limited & Managing Director

Cotec Healthcare Limited was incorporated in the year 1998.

Mr. Harsh Tiwari serves as Managing Director and CEO of the company.

Cotec Healthcare Limited FAQ

• Q1. What is the business of Cotec Healthcare Limited?

  It is an Indian pharmaceutical CDMO offering formulation development & commercial manufacturin alongwith dosage forms including injectables, tablets, capsules, syrups, eye/ear drops and more.

• Q2. Why is the company raising funds via IPO?

  Cotec Healthcare is raising funds via IPO to expand its manufacturing capacity with new facilities for high-growth products to support future growth.

• Q3. What is the size of the issue and where will it list?

  The issue size of the IPO includes a fresh issue of ₹295 crore and an OFS of 0.60 Cr equity shares. It will be listed on the BSE & NSE platform.

• Q4. What are the risks to an investor?

  Risks points for this IPO include industry regulation, customer concentration risk, input cost volatility and competitive pressures in the pharma CDMO segment.

• Q5. What are the potential upsides?

  Potential upsides to invest in the IPO are growing outsourcing in pharma manufacturing, capacity expansion, strong financial growth and broad formulation capabilities.

• Q6. How to apply for the IPO?

  You can apply for the IPO via ASBA through your bank’s netbanking or UPI with your Demat account when the IPO window opens through your broker or bank.

• Q 7. When is the tentative listing date?

  Expected listing date is yet to be announced.

For more amazing blogs click here (IPO Corner).